Update: SCENESSE® in DNA Repair
CLINUVEL PHARMACEUTICALS LTD provided today a clinical update on the use of...
Read More
CLINUVEL Annual General Meeting 2020
CLINUVEL PHARMACEUTICALS LTD’s 2020 Annual General Meeting (AGM) will be held on...
Read More
Media Release - First patient dosed in SCENESSE® DNA Repair Program
Xeroderma pigmentosum (XP) patient receives SCENESSE® treatment In the search for a...
Read More
First patient dosed in SCENESSE® DNA Repair Program
Xeroderma pigmentosum (XP) patient receives SCENESSE® treatment CLINUVEL PHARMACEUTICALS LTD today announced...
Read More
Media Release (ASX) - CLINUVEL progresses innovative DNA Repair Program
Drug tested to protect skin and regenerate DNA, firstly in XP patients...
Read More
Media Release – New drug to repair damaged skin and reduce skin cancer risk
Figure 1: CLINUVEL’s DNA Repair Program aims to confirm that intervention with...
Read More
CLINUVEL Full Year Results 2020
CLINUVEL REPORTS PROFIT, RENVESTING IN BUSINESS Fourth consecutive annual positive net cash...
Read More
Lapse and Forfeit of Unlisted Conditional Performance Rights
CLINUVEL PHARMACEUTICALS LTD wishes to advise in accordance with the terms and...
Read More